Premium
Is it beneficial for patients with pT1‐2N1M0 breast cancer to receive p ostmastectomy radiotherapy? An analysis based on RecurIndex assay
Author(s) -
Zhang Lina,
Zhou Mengli,
Liu Yueping,
Du Furong,
Tang Jiyu,
Wang Ning,
Song Chao,
Geng Cuizhi,
Duan Huijun
Publication year - 2021
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.33730
Subject(s) - breast cancer , radiation therapy , medicine , cancer , oncology
The benefit of postmastectomy radiotherapy (PMRT) for pT1‐2N1M0 breast cancer patients currently remains controversial. This study was conducted to investigate whether pT1‐2N1M0 breast cancer patients could benefit from PMRT based on RecurIndex assay. The clinical data of 213 pT1‐2N1M0 breast cancer patients were retrospectively analyzed. Through RecurIndex assay, 81 cases were assessed as the low risk, and 132 as the high risk. Compared to low‐risk patients, high‐risk patients especially those not receiving PMRT had a significantly increased risk of recurrence and metastasis, and worse 7‐year local‐regional recurrence‐free interval (LRFI), distance recurrence‐free interval (DRFI) and recurrence‐free survival (RFS) rates. PMRT‐based subgroup analysis indicated no significant differences between the low‐risk patients with and without PMRT in 7‐year LRFI, DRFI, RFS and overall survival (OS) rates, but apparent differences were all shown between the high‐risk patients with and without PMRT in 7‐year LRFI, DRFI, RFS and OS rates. Overall, for pT1‐2N1M0 breast cancer patients at low risk of recurrence and metastasis stratified by RecurIndex assay, there may be a phenomenon of no PMRT benefits, while for those at high risk, use of PMRT may produce survival benefits.